Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection

Kumada, Hiromitsu; Suzuki, Yoshiyuki; Ikeda, Kenji; Toyota, Joji; Karino, Yoshiyasu; Chayama, Kazuaki; Kawakami, Yoshiiku; Ido, Akio; Yamamoto, Kazuhide; Takaguchi, Koichi; Izumi, Namiki; Koike, Kazuhiko; Takehara, Tetsuo; Kawada, Norifumi; Sata, Michio; Miyagoshi, Hidetaka; Eley, Timothy; McPhee, Fiona; I. Damokosh, Andrew; Ishikawa, Hiroki; Hughes, Eric

doi:10.1002/hep.27113

Public

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection

Published in Hepatology • Mar 6, 2014

Authors:

Hiromitsu Kumada

Yoshiyuki Suzuki

Kenji Ikeda

Abstract

UNLABELLED: All-oral combinations of direct-acting antivirals may improve efficacy and safety outcomes for patients with hepatitis C virus (HCV) infection, particularly those who are poor candidates for current interferon/ribavirin-based regimens. In this open-label, phase 3 study, 135 interferon-in...

Subject

Daclatasvir

Genotype

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!